Improved policy visibility and cost controls support Kingmed's margin recovery

Overview

This report summarizes key points from management's discussion at Kingmed's China Healthcare Corporate Day 2026. Management focused on improved policy visibility in the medical testing industry, the company's multiple cost-control levers, and its unchanged 2026 operating guidance. Goldman Sachs believes Kingmed, as China's leading independent clinical laboratory player, is well positioned to benefit from industry supply rationalization, rising outsourcing penetration, and the advancement of centralized production.

Core views

The core views are: first, the path for medical testing service pricing reform is clearer, with national guidance expected to be finalized in 2026 and implemented nationwide in 2027, making pricing more standardized and potentially lower; second, the incremental impact from anti-corruption and package unbundling policies is limited, as most provinces completed package unbundling in 2025 and the company has not seen a meaningful business slowdown after the May 2026 anti-corruption rules; third, regional capacity centers, automation, supplier consolidation, and competition among multiple suppliers will help the company reduce costs; fourth, while price cuts may depress ASP, they could stimulate demand, increase hospitals' willingness to outsource, and accelerate industry consolidation, with leading companies able to offset pressure through scale, procurement savings, and centralized production.

Analysis framework

The report assesses Kingmed's medium- to long-term recovery path based on management remarks at the corporate day, the timing of industry policies, cost structure, and valuation framework, together with factors including industry supply rationalization, outsourcing penetration, market share gains, procurement bargaining power, and margin metrics.

Methodology notes

• Meeting-notes frameworkManagement discussion

  Extract policy, cost, and guidance changes from the IR Director's remarks

  The report uses management's comments on policy visibility, cost controls, and 2026 operating guidance as key evidence to assess the industry environment and the company's earnings recovery.

• Valuation method5-year exit P/E method

  Estimate the 12-month target price using a 5-year exit P/E and discounting

  The target price is Rmb36, based on valuation assumptions including a 9.5% discount rate and 21.8x P/E for global comparable companies.

• Factor frameworkGS Factor Profile

  Growth, financial returns, valuation multiples, and composite percentile

  Goldman Sachs Factor Profile is used to compare a stock's growth, financial returns, valuation multiples, and overall characteristics against the market and industry peers.

• M&A scenario frameworkM&A Rank

  Rate covered companies from 1 to 3 by probability of being acquired

  The report discloses Goldman Sachs' general M&A Rank framework, but the main text does not provide a specific M&A rating for Kingmed.

Asset mapping & comparison

Structured mapping from thesis to named assets (strengths, weaknesses, peers, risks).

• Kingmed (603882.SS)

  Covered company, leading player in China's ICL industry

  Strengths

  Improved policy visibility, progress in regional capacity centers, procurement cost reductions, scale advantages, and opportunities from industry consolidation.

  Weaknesses

  Margins remain under pressure in the post-pandemic period, demand for advanced testing is weak, and accounts receivable risk is still a concern for investors.

  Comparison

  Compared with smaller ICL players, leading companies are more likely to offset price declines through scale, centralized production, and supply-chain bargaining power.

  Risks

  Outsourcing demand recovers more slowly than expected, advanced testing demand remains weak for longer, VBP and local procurement create stronger pricing pressure, and industry consolidation progresses more slowly than expected.

• China medical testing / ICL industry

  The industry in which the company operates and the core backdrop for the investment thesis

  Strengths

  Lower prices may stimulate demand, while DRG/DIP and tighter compliance may increase hospitals' outsourcing incentives and drive industry consolidation.

  Weaknesses

  Nationwide pricing standardization may lower medical testing service prices, and short-term industry profitability may remain under pressure.

  Comparison

  Rising industry concentration will benefit leading companies with scale, automation, and centralized procurement capabilities.

  Risks

  There is uncertainty around the pace of policy execution, local procurement pressure, and the speed of demand recovery.

Key data

• Report date2026-06-29The report header shows a publication time of 11:03 CST on June 29, 2026.
• Covered companyKingmed (603882.SS)Both the report title and disclosure section refer to Kingmed.
• RatingBuyGoldman Sachs maintains a Buy rating on Kingmed.
• 12-month target priceRmb36Valuation is based on the 5-year exit P/E method.
• Disclosed current priceRmb22.16The company-specific disclosure section lists Kingmed's price as Rmb22.16.
• Implied upsideAbout 62.5%Calculated from the Rmb36 target price and the disclosed current price of Rmb22.16.
• 2026 revenue guidanceHigh single-digit growthThe company maintains its full-year 2026 revenue growth target.
• 2026 margin guidanceNet margin to rise above 5%Profit growth is expected to significantly outpace revenue growth.
• Reagent cost shareAbout 57%-58%Management said reagent costs accounted for about 57%-58% of 2025 costs.
• Policy timelineFinalized in 2026, implemented nationwide in 2027Refers to the expected timing of national guidance for medical testing service pricing reform.
• Progress of regional capacity centersChangsha and Zhengzhou operational; Suzhou under construction; Chengdu and Northeast China in planningIntended to handle non-urgent testing and improve automation and centralized production efficiency.

Impact & implications

If pricing reform leads to more standardized and lower prices nationwide, it may create short-term ASP pressure, but it could also increase testing demand and hospitals' willingness to outsource. For leaders like Kingmed, tighter compliance and supply-side rationalization are likely to improve the competitive landscape, while the company can offset pricing pressure through scale advantages, procurement savings, centralized capacity, and automation, thereby supporting margin recovery.

Risks

• Industry outsourcing demand recovers more slowly than expected.
• Demand for advanced testing remains weak.
• VBP and local procurement policies intensify pricing pressure.
• Industry consolidation progresses more slowly than expected.
• Accounts receivable collection falls short of expectations.

What to watch

• The pace of industry consolidation and Kingmed's market share gains.
• The margin recovery trajectory, especially whether net margin can rise above 5%.
• Progress in accounts receivable collection.
• Whether guidance for medical testing service pricing reform is finalized as expected in 2026 and implemented nationwide in 2027.
• Progress in regional capacity centers and automated laboratory construction.